NASDAQ Stocks
· Feb 8, 2025 9:00 PM EST
Not market news
Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in Wet Age-Related Macular Degeneration
EYLEA HD shows sustained vision and anatomical improvements over three years, allowing extended dosing intervals in wAMD patients.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
